News

The latest SeraNovian developments

SeraNovo Enters into a second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase inhibitor

 

Leiden, May 18th, 2020: SeraNovo Enters into a second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase inhibitor SeraNovo B.V. today announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilising its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability.  The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.  After our initial licence announcement in October 2019, SeraNovo is pleased to extend our relationship with Carna to include the formulation of another promising active ingredient. This expansion of our partnership with an industry leader is a great development towards wide spread adoption of our breakthrough formulation technology.

SeraNovo moved to BioPartner Building 1

 

Leiden, 16th of January 2020. SeraNovo B.V. is pleased to announce that it has moved its laboratory and management activities to BioPartner 1 at  the J.H. Oortweg 21. As a start-up the company managed to grow its business in a short time resulting in more employees and a doubling of the laboratory space. The new premises allow for the acquisition of new equipment to increase the analytical capabilities, as well as expand the current capacity. With this location the company is right in the heart of Leiden Bio Sciencepark with many possibilities to collaborate with other partners.  For the contact address please use the following link.

SeraNovo Enters into License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase inhibitor

 

Leiden, October 4th, 2019. SeraNovo B.V. today announced that it has signed an License Agreement with Carna Biosciences, Inc., a company engaged in drug development specializing in the development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with an increased bioavailability. Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on constituents that are for oral administration or broadly used in the industry. The final formulation includes an optimized combination of a DES, one or more polymeric precipitation inhibitors and Carna’s Kinase inhibitor.

This website uses cookies to track the usage of it.

More info